1. Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B, Bernstein JA, Bindslev-Jensen C, Brzoza Z, Buense Bedrikow R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018; 73:1393–1414.
2. Sánchez-Borges M, Asero R, Ansotegui IJ, Baiardini I, Bernstein JA, Canonica GW, Gower R, Kahn DA, Kaplan AP, Katelaris C, et al. Diagnosis and treatment of urticaria and angioedema: a worldwide perspective. World Allergy Organ J. 2012; 5:125–147.
3. Lee N, Lee JD, Lee HY, Kang DR, Ye YM. Epidemiology of chronic urticaria in Korea using the Korean health insurance database, 2010–2014. Allergy Asthma Immunol Res. 2017; 9:438–445.
4. MacDonald SM. Potential role of histamine releasing factor (HRF) as a therapeutic target for treating asthma and allergy. J Asthma Allergy. 2012; 5:51–59.
5. Xu A, Bellamy AR, Taylor JA. Expression of translationally controlled tumour protein is regulated by calcium at both the transcriptional and post-transcriptional level. Biochem J. 1999; 342:683–689.
6. Gachet Y, Tournier S, Lee M, Lazaris-Karatzas A, Poulton T, Bommer UA. The growth-related, translationally controlled protein P23 has properties of a tubulin binding protein and associates transiently with microtubules during the cell cycle. J Cell Sci. 1999; 112:1257–1271.
7. MacDonald SM, Lichtenstein LM, Proud D, Plaut M, Naclerio RM, MacGlashan DW, Kagey-Sobotka A. Studies of IgE-dependent histamine releasing factors: heterogeneity of IgE. J Immunol. 1987; 139:506–512.
8. Schroeder JT, Lichtenstein LM, MacDonald SM. An immunoglobulin E-dependent recombinant histamine-releasing factor induces interleukin-4 secretion from human basophils. J Exp Med. 1996; 183:1265–1270.
9. Schroeder JT, Lichtenstein LM, MacDonald SM. Recombinant histamine-releasing factor enhances IgE-dependent IL-4 and IL-13 secretion by human basophils. J Immunol. 1997; 159:447–452.
10. Vonakis BM, Macglashan DW Jr, Vilariño N, Langdon JM, Scott RS, MacDonald SM. Distinct characteristics of signal transduction events by histamine-releasing factor/translationally controlled tumor protein (HRF/TCTP)-induced priming and activation of human basophils. Blood. 2008; 111:1789–1796.
11. Kang HS, Lee MJ, Song H, Han SH, Kim YM, Im JY, Choi I. Molecular identification of IgE-dependent histamine-releasing factor as a B cell growth factor. J Immunol. 2001; 166:6545–6554.
12. Vonakis BM, Sora R, Langdon JM, Casolaro V, MacDonald SM. Inhibition of cytokine gene transcription by the human recombinant histamine-releasing factor in human T lymphocytes. J Immunol. 2003; 171:3742–3750.
13. Kim M, Min HJ, Won HY, Park H, Lee JC, Park HW, Chung J, Hwang ES, Lee K. Dimerization of translationally controlled tumor protein is essential for its cytokine-like activity. PLoS One. 2009; 4:e6464.
14. Kawakami T, Kashiwakura J, Kawakami Y. Histamine-releasing factor and immunoglobulins in asthma and allergy. Allergy Asthma Immunol Res. 2014; 6:6–12.
15. Wantke F, MacGlashan DW, Langdon JM, MacDonald SM. The human recombinant histamine releasing factor: functional evidence that it does not bind to the IgE molecule. J Allergy Clin Immunol. 1999; 103:642–648.
16. Huang X, Li Z, Sun R. Synergistic actions of histamine-releasing factor and histamine releasing factor-reactive IgE in chronic urticaria. Int Arch Allergy Immunol. 2017; 172:27–32.
17. Jin XH, Lim J, Shin DH, Maeng J, Lee K. Dimerized translationally controlled tumor protein-binding peptide ameliorates atopic dermatitis in NC/Nga mice. Int J Mol Sci. 2017; 18:256.
18. Ye YM, Park JW, Kim SH, Choi JH, Hur GY, Lee HY, Lee EH, Park HS. Clinical evaluation of the computerized chronic urticaria-specific quality of life questionnaire in Korean patients with chronic urticaria. Clin Exp Dermatol. 2012; 37:722–728.
19. Ye YM, Jin HJ, Hwang EK, Nam YH, Kim JH, Shin YS, Park HS. Co-existence of chronic urticaria and metabolic syndrome: clinical implications. Acta Derm Venereol. 2013; 93:156–160.
20. Konstantinou GN, Asero R, Maurer M, Sabroe RA, Schmid-Grendelmeier P, Grattan CE. EAACI/GA
2LEN task force consensus report: the autologous serum skin test in urticaria. Allergy. 2009; 64:1256–1268.
21. Lee MF, Lin TM, Liu SW, Chen YH. A rapid method of detecting autoantibody against FcεRIα for chronic spontaneous urticaria. PLoS One. 2014; 9:e109565.
22. Ye YM, Yang EM, Yoo HS, Shin YS, Kim SH, Park HS. Increased level of basophil CD203c expression predicts severe chronic urticaria. J Korean Med Sci. 2014; 29:43–47.
23. Kuehn HS, Radinger M, Gilfillan AM. Measuring mast cell mediator release. Curr Protoc Immunol. 2010; Chapter 7:Unit7.38.
24. Kashiwakura JC, Ando T, Matsumoto K, Kimura M, Kitaura J, Matho MH, Zajonc DM, Ozeki T, Ra C, MacDonald SM, et al. Histamine-releasing factor has a proinflammatory role in mouse models of asthma and allergy. J Clin Invest. 2012; 122:218–228.
25. Ferrer M, Nuñez-Córdoba JM, Luquin E, Grattan CE, De la Borbolla JM, Sanz ML, Schwartz LB. Serum total tryptase levels are increased in patients with active chronic urticaria. Clin Exp Allergy. 2010; 40:1760–1766.
26. Siles R, Xu M, Hsieh FH. The utility of serum tryptase as a marker in chronic spontaneous urticaria. Acta Derm Venereol. 2013; 93:354–355.
27. Okayama Y. Oxidative stress in allergic and inflammatory skin diseases. Curr Drug Targets Inflamm Allergy. 2005; 4:517–519.
28. Hosoki K, Gandhe R, Boldogh I, Sur S. Reactive oxygen species (ROS) and allergic responses. In : Laher I, editor. Systems biology of free radicals and antioxidants. Berlin: Springer;2014. p. 3239–3266.
29. Doré KA, Kashiwakura JI, McDonnell JM, Gould HJ, Kawakami T, Sutton BJ, Davies AM. Crystal structures of murine and human Histamine-Releasing Factor (HRF/TCTP) and a model for HRF dimerisation in mast cell activation. Mol Immunol. 2018; 93:216–222.
30. Lee H, Lee K. Dimerized translationally controlled tumor protein increases interleukin-8 expression through MAPK and NF-κB pathways in a human bronchial epithelial cell line. Cell Biosci. 2018; 8:13.
31. Gilfillan AM, Tkaczyk C. Integrated signalling pathways for mast-cell activation. Nat Rev Immunol. 2006; 6:218–230.
32. Lampinen M, Carlson M, Håkansson LD, Venge P. Cytokine-regulated accumulation of eosinophils in inflammatory disease. Allergy. 2004; 59:793–805.
33. Shakoory B, Fitzgerald SM, Lee SA, Chi DS, Krishnaswamy G. The role of human mast cell-derived cytokines in eosinophil biology. J Interferon Cytokine Res. 2004; 24:271–281.
34. Lorenzo GD, Mansueto P, Melluso M, Candore G, Cigna D, Pellitteri ME, Salvo AD, Caruso C. Blood eosinophils and serum eosinophil cationic protein in patients with acute and chronic urticaria. Mediators Inflamm. 1996; 5:113–115.
35. Tedeschi A, Asero R, Marzano AV, Lorini M, Fanoni D, Berti E, Cugno M. Plasma levels and skin-eosinophil-expression of vascular endothelial growth factor in patients with chronic urticaria. Allergy. 2009; 64:1616–1622.